A keeper from the swamp: steelyeye Sunday, 0
Post# of 72447
(Total Views: 330)
Posted On: 07/15/2019 8:47:44 AM
A keeper from the swamp:
steelyeye Sunday, 07/14/19 08:35:59 PM
Re: None 0
Post # of 267441
Such vehemence toward Leo is unfounded. The CEO and management team have actually accomplished quite a bit in the last several months, but you may have missed these. The year started with receiving a new Brilacidin patent, followed by completion of gastric testing supporting development of an oral dosage form to treat IBD, with clinical development now underway.
Leo then established a European subsidiary for the company and increased his equity stake (late January), and the company received a new patent for compounds used to treat oral mucositis using Brilacidin. (mid-February).
The European Medicines Agency granted IPIX a swift meeting after request for meeting (two weeks interim), followed by the company reporting enhancements in manufacturing Brilacidin for a phase 3 study (April 9th).
On May 1st the company reported receiving the FDA minutes from their end of phase 2 meeting, "helping to guide the company's planned phase 3 program for Brilacidin oral rinse to decrease the incidence of severe oral mucositis."
On May 16th the company announced a non-binding term sheet with a global Pharma to develop Brilacidin for Ulcertaive Proctitis/Proctosigmoiditis.
On June 6th the company signed an agreement for advanced oral tablet technology with a company that has a prior and possibly ongoing relationship with Novartis, where President and Chief Medical Officer Arthur Bertolino, MD, PHD, MBA used to work.
I’d say Leo earned his cash, and if he signs a deal and the share price takes off, Leo has plenty of shares to start a 10b5-1 plan for himself if he wishes.
Press releases for the above summary can be found at the company website.
Go IPIX!!!
steelyeye Sunday, 07/14/19 08:35:59 PM
Re: None 0
Post # of 267441
Such vehemence toward Leo is unfounded. The CEO and management team have actually accomplished quite a bit in the last several months, but you may have missed these. The year started with receiving a new Brilacidin patent, followed by completion of gastric testing supporting development of an oral dosage form to treat IBD, with clinical development now underway.
Leo then established a European subsidiary for the company and increased his equity stake (late January), and the company received a new patent for compounds used to treat oral mucositis using Brilacidin. (mid-February).
The European Medicines Agency granted IPIX a swift meeting after request for meeting (two weeks interim), followed by the company reporting enhancements in manufacturing Brilacidin for a phase 3 study (April 9th).
On May 1st the company reported receiving the FDA minutes from their end of phase 2 meeting, "helping to guide the company's planned phase 3 program for Brilacidin oral rinse to decrease the incidence of severe oral mucositis."
On May 16th the company announced a non-binding term sheet with a global Pharma to develop Brilacidin for Ulcertaive Proctitis/Proctosigmoiditis.
On June 6th the company signed an agreement for advanced oral tablet technology with a company that has a prior and possibly ongoing relationship with Novartis, where President and Chief Medical Officer Arthur Bertolino, MD, PHD, MBA used to work.
I’d say Leo earned his cash, and if he signs a deal and the share price takes off, Leo has plenty of shares to start a 10b5-1 plan for himself if he wishes.
Press releases for the above summary can be found at the company website.
Go IPIX!!!
(3)
(0)